Novavax Expects to Make Omicron COVID-19 Vaccine by Fall – National

Novavax Inc NVAX.O announced on Friday that it expects to provide a COVID-19 vaccine targeting Omicron in the fourth quarter as it accelerates the development of vaccines to protect against subvariants BA.4 and BA.5.

The U.S. FDA on Thursday recommended that manufacturers of COVID-19 vaccines change the design of their booster vaccines starting this fall to include components tailored to combat Omicron’s currently dominant BA.4 and BA.5 subvariants are.


Click here to play the video:







How reliable are Omicron rapid antigen tests?


How reliable are Omicron rapid antigen tests? – April 18, 2022

Novavax expects additional preclinical data on vaccines tailored to the rapidly spreading subvariants of Omicron in late summer or fall.

The story continues below the ad

The company’s vaccine, which is based on an earlier strain of the virus, has not yet been approved in the United States and is currently under review by the US Food and Drug Administration.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Shounak Dasgupta)

https://globalnews.ca/news/8961786/novavax-covid-vaccine-omicron/ Novavax Expects to Make Omicron COVID-19 Vaccine by Fall – National

Hung

Inter Reviewed is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – admin@interreviewed.com. The content will be deleted within 24 hours.

Related Articles

Back to top button